Medical Ethics Manager – Alexion

AstraZeneca / Alexion; Camden Town; On-site; GBP 90,000 - 115,000; Full time

Job summary

AstraZeneca / Alexion is seeking a Medical Ethics Manager to support its UK & Ireland Rare Disease portfolio. As a Nominated Signatory, you will guide compliant, patient-centred activities and oversee ethical review processes with human oversight of AI-enabled tools.

You will provide evidence-based advice, strengthen governance and collaborate with cross-functional teams to ensure ABPI compliance and UK regulatory alignment across Medicines Affordability, Medical Affairs and Signatory functions.

Qualifications

• Registered physician or pharmacist eligible to act as a Nominated Signatory.
• Experience in Medical Affairs, medical review, signatory work or pharmaceutical compliance.
• Strong working knowledge of the ABPI Code and UK requirements.
• Clear communication and effective cross-functional partnering.

Responsibilities

• Review and approve materials as a Nominated Signatory, applying ABPI/IPHA Codes and Alexion standards.
• Advise cross-functional partners on medical ethics and compliance questions; escalate high-risk matters.
• Maintain review procedures, checklists and controls; support training and continuous improvement.
• Use approved digital tools to improve review quality and turnaround; protect confidential data.
• Monitor data and identify improvements; provide updates to Medical Ethics Lead.

Skills

Medical ethics

Signatory experience

Cross-functional partnering

Strong communication

Education

Medical degree (MD/MBBS) or Pharmacist qualification

Tools

AI-enabled review tools

ABPI Code knowledge

Job description

Role overview

Alexion is seeking a Medical Ethics Manager to support its UK & Ireland Rare Disease business. As a Nominated Signatory and trusted cross-functional partner, you will help teams deliver patient-centred, scientifically sound activities in line with applicable Codes, legislation and company standards. You will provide pragmatic, evidence-based advice and strengthen review processes, capability and insight, including the responsible use of approved AI-enabled tools with appropriate human oversight.

Key responsibilities

• Review and approve agreed promotional and non-promotional materials, activities and meetings as a Nominated Signatory, applying ABPI/IPHA Codes, relevant legislation and Alexion standards.
• Advise cross-functional partners on medical ethics and compliance questions; elevate novel, high-risk or precedent-setting matters appropriately.
• Maintain review procedures, checklists and operational controls, and support training, coaching, signatory validation and continuous improvement.
• Use approved digital and AI-enabled tools to improve review quality, consistency, insight and turnaround; validate outputs and protect confidential, personal and proprietary information.
• Monitor review data and recurring themes, identify workflow and training improvements, and provide updates and delivery-risk escalations to the Medical Ethics Lead.

Candidate profile

Essential: Registered physician or pharmacist eligible to act as a Nominated Signatory; experience in Medical Affairs, medical review, signatory work or pharmaceutical compliance; strong working knowledge of the ABPI Code and relevant UK requirements; clear communication, sound ethical judgement and effective cross-functional partnering. Candidates should be comfortable using approved digital tools responsibly and handling confidential information with discretion.

Desirable: Rare-disease or complex patient-pathway experience; knowledge of the IPHA Code; experience with AI-enabled review or workflow improvement; and coaching, training or change-adoption experience.

Role details and application

• Employer: AstraZeneca / Alexion (Alexion, AstraZeneca Rare Disease)
• Location: St Pancras, London
• Type: Full-time
• Working pattern: Average expectation of at least three days per week in the office; individual flexibility is considered
• Salary: Competitive, plus excellent benefits
• Closing date: 10 November 2026